Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients
Status:
Recruiting
Trial end date:
2023-12-15
Target enrollment:
Participant gender:
Summary
Breast cancer is the commonest malignancy among females and one of the leading causes of
death worldwide. Many drugs have been developed over the years to try to extend survival
among these patients including cyclin dependant kinase inhibitors. Cyclin dependant kinase
inhibitors (CDK inhibitors) mainly Palbociclib (PAL), ribociclib (RIB) and abemaciclib (ABM)
are approved for treatment of hormone receptor positive, HER2 negative advanced breast cancer
in the 1st line and subsequent lines in combination with aromatase inhibitors or fulvestrant.
Studies showed that they extend progression free survival and recently they showed overall
survival benefit. In this study investigators compare Palbociclib+ fulvestrant VS Ribociclib
+ fulvestrant as a second line treatment in metastatic ER+ve her2 -ve BC in oncology center
mansoura university egyptian patients.